Konner, Jason A.

Publications

Sort by

Co-Author Network

selected publications

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 20
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of gynecologic oncology. 2020 Academic Article GET IT
Times cited: 17
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 23
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate. EJNMMI research. 2018 Academic Article GET IT
Times cited: 86
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 Academic Article GET IT
Times cited: 5
Genetic predisposition to bevacizumab-induced hypertension. Gynecologic oncology. 2017 Academic Article GET IT
Times cited: 13
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic oncology. 2017 Academic Article GET IT
Times cited: 50
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. 2017 GET IT
Times cited: 317
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 126
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA oncology. 2016 Academic Article GET IT
Times cited: 173
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecologic oncology. 2015 Academic Article GET IT
Times cited: 50
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 19
Breaking down the evidence for bevacizumab in ovarian cancer. The oncologist. 2015 Editorial Article GET IT
Times cited: 3
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 18
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 3
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 5
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 209
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 10
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012 Academic Article GET IT
Times cited: 27
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 39
New drugs for ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Review GET IT
Times cited: 7
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 8
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 38
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 32
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 82
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 147
Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 9
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 34
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. The oncologist. 2009 Academic Article GET IT
Times cited: 53
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 184
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 125
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 12
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up. Cancer. 2008 Academic Article GET IT
Times cited: 3
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 67
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nuclear medicine and biology. 2008 Academic Article GET IT
Times cited: 45
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. European journal of gynaecological oncology. 2008 Academic Article GET IT
Times cited: 16
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007 Academic Article GET IT
Times cited: 154
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 123
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 52
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 55
Pancreatic cancer: epidemiology, genetics, and approaches to screening. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 22
Alternative careers for physicians. JAMA. 1998 Editorial Article GET IT
Times cited: 2
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. Journal of virology. 1998 Academic Article GET IT
Times cited: 122
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell. 1994 Academic Article GET IT
Times cited: 611
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer chemotherapy and pharmacology. 1990 Academic Article GET IT
Times cited: 14

more ...

less ...

Background

education and training

M.D., Stanford University School of Medicine 1999
B.S., Yale University 1994

Contact

full name

Jason A. Konner

VIVO Weill Cornell Medical College

Jason A. Konner Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name